Our Focus

Cardiac Intelligence

Kardigan is breaking the current cycle of cardiovascular drug discovery and development with a modernized approach.

Cardiac Intelligence drives our singular aim to deliver multiple important medicines at an unprecedented pace. Obsessed with eliminating cardiovascular disease, Kardigan brings an unmatched level of focus, expertise, and passion to modernize the discovery and development of treatments targeted to an individual’s disease.

For decades, cardiovascular disease has been the number one cause of death worldwide. In the U.S. alone, it claims more lives than all cancers and accidents combined. Despite this, conventional approaches to drug development that require long and expensive outcomes clinical trials, intermittent industry focus, and limited investment have resulted in incremental therapeutic advancements with minimal improvement in patient outcomes overall.

At Kardigan, we offer something different. While traditional R&D focuses mostly on treating broad populations defined by symptoms, Kardigan is focused on treating the causal biology of cardiovascular disease and areas where no treatments currently exist. We cannot continue to take the same approach to drug development and expect to get a different outcome, much less a better result.

Kardigan’s Blueprint for Cardiac Intelligence

Icon Target Root cause

Target the Root Cause of Disease

Focus treatments on the biological drivers of disease — not just symptoms — to treat the right patients​
Icon Drive Intelligent Development

Drive Intelligent Development

Use data-rich and adaptive clinical trial designs to identify patients most likely to benefit
Icon Build Data Rich Pipeline

Build a Data-Rich Pipeline

Integrate proprietary, real world, patient-derived insights to inform future targets and indications​

Our three late-stage clinical programs cover many key disease mechanisms in the integrated cardiovascular system. Together, they generate new insights and data to fuel Kardigan’s R&D efforts, inform clinical trial design, and potentially reduce the time and cost to develop meaningful new medicines through:

Novel Drug Discovery Tools​

  • Proprietary platforms and biological models: cellular, animal, metabolomic, and proteomic​
  • Creates a foundation of unique biological insight​

New Paradigm in Cardiovascular Disease Clinical Trial Excellence​

  • Adaptive trial design and enrichment strategy turbocharged by Prolaio platform​
  • Enables high density data designed to accelerate progress and improve success rate

AI / Machine Learning Platform​

  • Prolaio and other software platforms generate and integrate data across discovery and development
  • All insights feed back into the system, reinforcing and improving the cycle